Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cogent Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Cogent Biosciences, Inc.

COGT

Cogent Biosciences, Inc.

About Cogent Biosciences, Inc.

Cogent Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Its core programs include bezuclastinib, a selective KIT inhibitor for systemic mastocytosis and gastrointestinal stromal tumors, and CGT4859, an FGFR2 inhibitor. The company aims to address unmet medical needs with targeted, innovative medicines for rare cancers and disorders, leveraging proprietary technology and strategic licensing.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Cogent Biosciences, Inc.

1
1
Cogent Biosciences, Inc. Cogent Biosciences Reports $97.4 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Cogent Biosciences, Inc. Cogent Biosciences Reports $328.9 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Cogent Biosciences, Inc. Cogent Biosciences Reports $80.9 Million Net Loss in Q3 2025 Amid Increased Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cogent Biosciences, Inc. Cogent Biosciences Reports $145.5 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cogent Biosciences, Inc. Cogent Biosciences Reports $72M Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cogent Biosciences, Inc. Cogent Biosciences Reports $255.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Cogent Biosciences, Inc. Cogent Biosciences Reports Increased Assets and Funding, Wider Net Losses in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments